The LIFE Cooperative includes world-class companies - from SMEs to startups - in the Life Sciences and Health Cluster of the Northern Netherlands.
QDI systems is a deep tech startup established in Groningen as a spin-off from Zernike Institute for Advanced Materials. Our technology relies on quantum dots – tiny nanoparticles which are the basis of a unique photosensitive ink, which we are developing as a platform to build imaging devices for medical applications.
From reinvigorating product portfolios to driving regulatory approvals, Regenity Biosciences is a trusted partner in regenerative medicine. Founded in 1997, Regenity is a trailblazer in soft and hard tissue regeneration. We bring curiosity, scientific rigor, and a sense of urgency to creating transformative medical and dental solutions.
Next-Gen Tracer for Infection Imaging Sabiad’s solution is a major innovation in the field of infection imaging. It uses monoclonal antibodies, making the diagnosis of Staphylococcus Areus related infections in the (orthopedic) implant area not only accurate but also fast and minimally invasive.
SE Factory is a Groningen-based manufacturer and developer of the EMDR Kit, a tool that supports therapists in trauma treatment. The company designs, develops and manufactures this equipment entirely in-house – from concept and prototype to production and global distribution. With its technical expertise in areas such as electronics and product development, SE Factory focuses on user-friendly, innovative solutions that make EMDR therapy more effective and comfortable.
Sencilia is an early-stage MedTech startup that was spun out of the University of Groningen. We specialize in micro and nanotechnology and are experts in developing bioinspired MEMS sensors. The mission of our company is to improve patient safety using our patent-pending MEMS sensor technology, and our first offering is an IV infusion flow monitoring device. Our smart hardware/software product will improve the safety of IV therapy, thereby enhancing patient outcomes and reducing healthcare costs associated with preventable adverse drug events.